A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS - Contacts and Locations

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

This study has been completed.
Information provided by NIH AIDS Clinical Trials Information Service

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002116

Locations


United States, California
	Mount Zion Med Ctr / UCSF
	San Francisco, California, United States, 94115
	UCSF - San Francisco Gen Hosp
	San Francisco, California, United States, 94110
	Los Angeles County - USC Med Ctr
	Los Angeles, California, United States, 90033

United States, Illinois
	Rush Presbyterian - Saint Luke's Med Ctr
	Chicago, Illinois, United States, 60612

United States, Maryland
	Johns Hopkins Hosp
	Baltimore, Maryland, United States, 21205

United States, North Carolina
	Univ of North Carolina Hosps
	Chapel Hill, North Carolina, United States, 27599

United States, Texas
	Park Plaza Hosp
	Houston, Texas, United States, 77004

United States, Washington
	Univ of Washington / Viral Disease Clinic
	Seattle, Washington, United States, 98122

Canada, British Columbia
	Univ of British Columbia / Univ Hosp
	Vancouver, British Columbia, Canada

Sponsors and Collaborators

Gilead Sciences